delhommeau

DELHOMMEAU Francois

pubmedlogo

Contacts

Team leader: Luc Douay

Administrative contact: Arnaud Noisette

Tel: +33 (0)1 49 28 46 38 - Fax: +33 (0)1 40 01 13 79

Faculté de médecine Pierre et Marie Curie – Site Saint-Antoine – 9th floor 
27, rue Chaligny – 75571 PARIS cedex 12

Team members

Prof./Associate prof. ; Research directors/scientists ; Physicians

BILHOU-NABERA Christele

MCU-PH 

 

CHAPEL Alain

Researcher

 

DELHOMMEAU Francois

PU-PH

HDR

DOUAY Luc

PU-PH (Team Leader)

HDR

GARCON Loic

PU-PH

HDR

GARDERET Laurent

MCU-PH

HDR

GORIN Norbert-Claude

PU-PH

HDR

LANDMAN-PARKER Judith

PU-PH

HDR

LAPILLONNE Hélène

PU-PH

HDR

LEGRAND Ollivier

PU-PH

HDR

LEVERGER Guy

PU-PH

HDR

PETIT Arnaud

PU-PH

HDR

ROUARD Hélène

MCU-PH

HDR

AUVRIGNON Anne

PH

 

CHAQUIN Michael

PH

 

BOUTROUX Hélène

CCA

 

LABOPIN Myriam

PH

 

MARZAC Christophe

PH

 

SUNER Ludovic

AHU

 

Post-doc and Contractual researcher

DARGHOUTH Dhouha

Post-doc

 

FLANDRIN-GRESTA Pascale

Post-doc

 

ROUSSEAU Guillaume

Post-doc

 

FRANCOIS-L'HOMME Sabine

Researcher

 

Engineers and Technicians

HARMAND Laurence

Engineer, PhD

 

HEBERT Nicolas

Assistant Engineer

 

JOLLY Severine

Assistant Engineer

 

KOBARI Ladan

Engineer, PhD

 

MARIE Tiffany

Assistant Engineer

 

MAZURIER Christelle

Engineer, PhD

 

CAVANNA Noémie

Technician

 

BADOGLIO Manuela

Study Coordinator (EBMT)

 

BEOHOU Eric

Study Coordinator (EBMT)

 

BOUMENDIL Ariane

Study Coordinator (EBMT)

 

DALISSIER Arnaud

Study Coordinator (EBMT)

 

FINEL Hervé

Study Coordinator (EBMT)

 

HOUHOU Mohamed

Study Coordinator (EBMT)

 

MAILHOL Audrey

Study Coordinator (EBMT)

 

POLGE Emmanuelle

Study Coordinator (EBMT)

 

LEMAITRE Jessica

Study Coordinator (EBMT)

 

PENISSON Eva

Study Coordinator (EBMT)

 

PhD and Master students

HIRSCH Pierre

PhD Student 

 

Research activity

Patients with haematological malignancies and those with irradiation-injured lesions have in common the alteration of the stem cell pool and the need for Hematopoietic Stem Cells (HSC), Mesenchymal Stem cells (MSC) and Red Blood Cell (RBC) transfusion support to repair tissue and bone marrow defects. In the general context of cell therapy and its clinical applications, the overall goal our group is based on the study, for therapeutic purposes, of the stem cells of human bone marrow (HSC and MSC) and of the pluripotent adult pool (iPS). Luc Douay's team is composed of 4 main workpackages.

WP1 RED BLOOD CELL PRODUCTION FOR TRANSFUSION MEDICINE which aim is the production of RBC from iPS for transfusion. The project is: (i) To understand the mechanisms controlling iPS/erythroid differentiation, (ii) The design of conditions for large scale industrial production of cRBCs.

WP2 STEM CELLS FOR TISSUE REPAIR : Two models are studied (i) plasticity and cellular communication in multiple myeloma in order to determine whether MSC isolated from adipose tissue (Ad-MSCs) of MM patients could be used for therapeutic purposes to improve bone lesions in patients, and (ii) generation of  hematopoietic stem cells from non-hematopoietic iPS in patients with hematological malignancies and acute irradiation syndrome and the study their hematopoeitic reconstitution capacity in the NOD/SCID mouse model as an innovative therapeutic strategy of hematopoietic syndrome.

WP3 MOLECULAR ABNORMALITIES IN MYELOID MALIGNANCIES : The project is to study molecular abnormalities in myeloid malignancies, particularly acute myeloid leukemia and myeloproliferative neoplasms, in adult and child. The project include the analysis of the clonal phylogeny of these malignancies and the role of certain mutations in the initiation of leukemia, and the use of the characteristics of leukemic stem cells as markers of residual disease.

WP4 EPIDEMIOLOGICAL SURVEY AND EVALUATION OF THE THERAPEUTIC EFFECT OF HSC GRAFT: The future developments of the EBMT Registry aim: (i) to better define the role of transplantation in specific subgroups of patients according to new biological makers, (ii) to define the best strategy to be adopted in terms of conditioning and type of donor regarding recent developments (comparison between double cord blood and direct intra-bone cord blood, evaluation of new drugs), (ii) to evaluate the best therapeutic option in high risk patients with refractory disease, (iv) to study the respective impact of different socio-economical parameters on the outcome of patients (v) to evaluate the cost of transplantation and to run different cost-effectiveness studies taking into account for quality of life

Publications:

Giarratana, M.-C., Rouard, H., Dumont, A., Kiger, L., Safeukui, I., Le Pennec, P.-Y., François, S., Trugnan, G., Peyrard, T., Marie, T., et al. (2011). Proof of principle for transfusion of in vitro-generated red blood cells. Blood 118, 5071–5079.

Rouzbeh, S., Kobari, L., Cambot, M., Mazurier, C., Hebert, N., Faussat, A.-M., Durand, C., Douay, L., and Lapillonne, H. (2015). Molecular signature of erythroblast enucleation in human embryonic stem cells. STEM CELLS 33, 2431–2441.

Delhommeau F. Effect of mutation order on myeloproliferative neoplasms.N Engl J Med. 2015 May 7;372(19):1865

Pronier E, Almire C, Mokrani H, Vasanthakumar A, Simon A, da Costa Reis Monte Mor B, Massé A, Le Couédic JP, Pendino F, Carbonne B, Larghero J, Ravanat JL, Casadevall N, Bernard OA, Droin N, Solary E, Godley LA, Vainchenker W, Plo I, Delhommeau F. Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors. Blood. 2011 Sep 1;118(9):2551-5.

Gorin NC, Labopin M, Piemontese S, Arcese W, Santarone S, Huang H, Meloni G, Ferrara F, Beelen D, Sanz M, Bacigalupo A, Ciceri F, Mailhol A, Nagler A, Mohty M; Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. T-cell-replete haploidentical transplantation versus autologous stem cell transplantation in adult acute leukemia: a matched pair analysis. Haematologica. 2015 Apr;100(4):558-64

Prediction of Allogeneic Hematopoietic Stem-Cell Transplantation Mortality 100 Days After Transplantation Using a Machine Learning Algorithm: A European Group for Blood and Marrow Transplantation Acute Leukemia Working Party Retrospective Data Mining Study. Shouval R, Labopin M, Bondi O, Mishan-Shamay H, Shimoni A, Ciceri F, Esteve J, Giebel S, Gorin NC, Schmid C, Polge E, Aljurf M, Kroger N, Craddock C, Bacigalupo A, Cornelissen JJ, Baron F, Unger R, Nagler A, Mohty M. J Clin Oncol. 2015 Oct 1;33(28):3144-51

Publications:

pubmedlogo

kourilsky.jpg

Centre De Rercherche (CdR) Saint-Antoine
INSERM - UMR S 938

Hôpital St-Antoine

Contact
Tél : +(33) 1 49 28 46 87

Activer le Plan

Saint-Antoine Research Center

The CRSA was renewed jointly by Inserm and UPMC as UMRS_938, for 5 years from January 2014 to December 2018.

Last publications

Presentation of the Centre

The CRSA regroups a very strong potential for biomedical research oriented towards both fundamental and translational research. Research is performed in association with the clinical and biological departments of the Saint-Antoine-Tenon-Armand Trousseau hospitals belonging to the same General Hospital Group. The CRSA is composed of 14 accredited research teams and one administrative team located mainly on the site of the Saint-Antoine hospital but also of hospital Armand Trousseau.

Scientific activities

Two scientific interacting orientations are identified: Research in Oncology and Haematology; and Research in Metabolism and Inflammation and Tissue Repair. They include several aspects of translational research : Fundamental; Preclinical; Pathophysiological and Aspects more specifically clinical.

Collective facilities and technological platforms

The Research Centre developed collective facilities (such as L2, L3 laboratories) but is also implicated in UPMC networks (for technologies such as Mass spectrometry, lipidomic and proteomic; Cell and tissue imagery and flow cytometry ; Imagery and functional exploration of small animals)